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Objective: To evaluate the efﬁcacy of andrographolide in treating adenomyosis and to test the hy-
pothesis that its efﬁcacy may depend on the nuclear factor-kappa-light-chain enhancer of activated B
cells (NF-kB) activation status in eutopic endometrium, which may be a proxy for the status in ade-
nomyotic foci.
Materials and methods: Twenty-four patients with transvaginal ultrasound-conﬁrmed adenomyosis
(excluding ovarian endometriomas) were recruited for this study after informed consent. All patients had
dysmenorrhea and/or heavy menstrual bleeding. All received andrographolide pill orally for 3 months
and were followed up for an additional 3 months. The primary outcome measures included the severity
of dysmenorrhea, as measured by the visual analog scale (VAS), and menstrual characteristics, such as
the amount of menses, all measured before and 3 and 6 months after the drug treatment. In addition, the
patients completed Clinical Global Impression rating scales at the end of the 6th month. Immunostaining
of the phosphorylated NF-kB p65 (p-p65) subunit was also performed for eutopic endometrium.
Results: Andrographolide treatment appeared to be well tolerated by the patients. Six months after
taking andrographolide, the average dysmenorrhea VAS score was decreased from the baseline level of
5.3 to 3.5. Twelve patients (50.0%) reported “marked” or “much” improvement, seven (29.2%) reported
“minimal improvement” and ﬁve (20.8%) reported “unchanged or worse”. The eutopic endometrial p-p65
staining levels were closely correlated with the satisfaction rating.
Conclusion: Andrographolide is effective in some patients with symptomatic adenomyosis, who have a
higher endometrial expression of the activated form of the NF-kB p65 subunit. Future independent
validation studies or randomized clinical trials may be needed to more precisely evaluate the efﬁcacy of
andrographolide.
Copyright © 2015, The Asia-Paciﬁc Association for Gynecologic Endoscopy and Minimally Invasive
Therapy. Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Adenomyosis, characterized by the presence of heterotopic
endometrial glands and stroma in the myometrium with adjacent
smooth muscle hyperplasia, is a fairly common gynecologic dis-
ease responsible for menorrhagia, dysmenorrhea, and subfertilityts of a patent on the use of
submitted to the Patent Bu-
ynecology Hospital, Shanghai
ad, Shanghai 200011, China.
for Gynecologic Endoscopy and Minimin women of reproductive age.1 Although the disease is estrogen
dependent, progestogenic agents are not very effective, and the
use of gonadotropin-releasing hormone (GnRH) agonists is
restricted by their short duration.2 Worse, the symptoms quickly
reappear after discontinuation of GnRH agonists therapy.3
Although the levonorgestrel-releasing intrauterine system has
been reported to have some efﬁcacy,4 side effects such as spotting
were nonetheless seen in one third of the women, and oligome-
norrhea was the most common complaint observed.4 Therefore,
the current arsenal for treatment of adenomyosis is limited. As
such, the deﬁnitive treatment for symptomatic adenomyosis is
hysterectomy,1 even though the decision to remove the uterus,
arguably an iconic symbol of womanhood, can be difﬁcult andally Invasive Therapy. Published by Elsevier Taiwan LLC. All rights reserved.
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new drug treatment currently on the horizon, as only 33 clinical
trials on adenomyosis have been registered at www.ClinicalTrials.
gov (accessed December 3, 2014), with only one Phase I trial that
evaluated the novel nonhormonal compound, bromocriptine, a
dopamine agonist.
Adenomyosis and endometriosis share uncannily many simi-
larities in disease deﬁnition, estrogen dependency, and some mo-
lecular aberrations. In endometriosis, the pathophysiological role of
nuclear factor kappa-light-chain enhancer of activated B cells (NF-
kB) has long been suspected5 and now well established.6e8 Simi-
larly, NF-kB seems to play a role in adenomyosis.9
Andrographolide (referred to as “Andro” from herein) is an
active ingredient chemically extracted from andrographis
(Andrographis paniculata), which has been used as a medicinal herb
in traditional Chinese medicine for the alleviation of inﬂammatory
disorders for thousands of years. Andro is known to be anti-in-
ﬂammatory10 and to interfere with NF-kB binding to DNA.11 Its
mechanism of action is shown to result from suppression of NF-kB
activation through covalent modiﬁcation of reduced cysteine 62 of
the p50 subunit12 and inhibition of p65 Ser536 phosphorylation.13
Not surprisingly, it is known to exert strong immunomodulatory
effects,14 and is reported to inhibit proinﬂammatory and angiogenic
mediators such as cyclooxygenase-2 (COX-2)11 and tissue factor
(TF),5 both of which are reportedly involved in adenomyosis.16,17
Andro has also been shown to be antinociceptive in animals.18,19
It has been shown to suppress the expression of oxytocin recep-
tor and modulate uterine contractility in adenomyosis,20,21 and
inhibit the expression of COX-2, vascular endothelial growth factor,
and TF in adenomyosis.22 Most remarkably, Andro, unlike many
other NF-kB inhibitors, is already commercially available with an
excellent safety proﬁle, and is a nonprescription medication in
China for the treatment of upper respiratory tract infections. A
recent clinical trial on the use of A. paniculata extract containing
30% total andrographolides to treat rheumatoid arthritis reported
encouraging results.23
We have previously reported the promising results on the off-
label use of valproic acid (VPA) to treat adenomyosis.24,25 Because
VPA is approved for treating epilepsy and bipolar disorder, which
are conspicuously labeled on the package, and, in the Chinese
culture, are disorders of the nervous system that carry, perhaps
unjustiﬁably, some negative connotation or even social stigma,
many patients balk at the idea of taking the drug after reading the
label, even though they are refractory to all existing therapeutics
and the only option they have is hysterectomy. A strained
patientedoctor relationship that is prevalent across China today
and a health care system that is not conducive to promoting clinical
trials certainly provides no help. In addition, there is concern that,
being a global histone deacetylase inhibitor as well as a pregnancy
category D drug, VPA may cause some unintended side effects.
Therefore, we sought to identify novel therapeutics for
adenomyosis.
Given the encouraging in vitro and in vivo results suggesting the
therapeutic potential of Andro20e22,26 and, equally important, its
safety proﬁle, we sought in this study to further evaluate the efﬁ-
cacy of Andro in patients with adenomyosis who presented with
complaints of dysmenorrhea and/or menorrhagia andwho also had
an enlarged uterus. These patients were refractory to nonsurgical
treatment and faced the only option of hysterectomy. The focus on
patients with adenomyosis complaining of dysmenorrhea/menor-
rhagia also poses few, if any, ethical challenges given the safety
proﬁle and makes recruitment much easier. We hypothesized that,
because the mode of action is mainly through suppression of NF-kB
activation, the efﬁcacy of Andro may depend on the NF-kB activa-
tion status in adenomyotic foci. Although it is difﬁcult to evaluatethe NF-kB activation status in adenomyotic foci without being
invasive, we hypothesized that the NF-kB activation status in
eutopic endometriummay be a proxy for the status in adenomyotic
foci.
Materials and methods
Patients
Twenty-four patients with transvaginal ultrasound-conﬁrmed
adenomyosis (excluding ovarian endometriomas) who visited
Shanghai Obstetrics and Gynecology Hospital, Fudan University
Shanghai Medical College (Shanghai, China) from October 2009 to
March 2010 were recruited for this study after obtaining informed
consent (Table 1). The diagnosis of adenomyosis in all patients was
made based on a combination of symptomatology, pelvic exami-
nation, and vaginal ultrasound evaluation by experienced physi-
cians. All patients had either dysmenorrhea, as reﬂected by the
visual analog scale (VAS) measurement and also based on gyne-
cological examination, or heavy menstrual bleeding, as measured
by the pictorial bleeding assessment chart (PBAC),27 or both con-
ditions (Table 1). All patients were premenopausal, with no history
of hormone therapy or intrauterine device use for 6 months prior
to recruitment. They were not pregnant or lactating, and had no
intention to get pregnant. They all had normal hepatic and renal
functions, as deﬁned by serum transaminases < 1.5 upper limit of
normal (ULN), bilirubin < 1.5  ULN, and creatinine < 2.0  ULN.
None of them had any psychiatric condition that would compro-
mise the full compliance with the study, nor did they have any
severe concomitant medical disorder, signiﬁcant cardiovascular
disease, major thromboembolic event in the last 6months, or Grade
3 or 4 bleeding.
During the recruitment, all patients were offered the option of
hysterectomy or the chance to try Andro. They all chose to try the
drug and were given the full explanation of the experimental na-
ture of this study and possible risks associated with it. Approval for
this pilot study was obtained from the local Ethics Committee at
Shanghai Obstetrics and Gynecology Hospital, Fudan University.
Treatment
All patients received Andro dripping pill (Tansly Pharmaceutics,
Tianjin, China; Fig. 1) orally starting at the 5th day of the menstrual
cycle, with 600 mg (containing 150-mg pure Andro) t.i.d. for 3
months, when no serious adverse effect was reported. The patients
stopped taking the pill when they had menstruation but resumed
at the 5th day of the menstrual cycle. For these patients, the treat-
ment was terminated at the end of the 3rd month after taking the
drug. The patients were then followed up for an additional 3
months. During treatment, clinical signs and symptoms were
monitored.
Outcome measures
The primary outcome measures were the severity of dysmen-
orrhea, as measured by a 10-cm VAS, and the uterine size by ul-
trasonographic measurement in length  width  height (in cm3).
The VAS and uterine size were measured before the drug treatment
and 3 months and 6 months after the drug treatment, respectively.
In addition, menstrual characteristics, such as duration of
menstruation (in days), estimated amount of menses (by the PBAC
method), and length of menstrual cycle (in days), were also
measured before and 3 months and 6 months after the drug
treatment.
Table 1
Characteristics of the 24 patients who were recruited to the study, along with the changes in primary and secondary outcome measures when available.
Variable name Before Andro treatment 3 mo after treatment 6 mo after treatment pa
Age (y) 40.2 (5.0) N/A N/A N/A
40.0 (30e50)
Gravidity, n (%)
0 5 (20.8) N/A N/A N/A
1 2 (8.3)
2 6 (25.0)
2þ 11 (45.8)
Parity, n (%)
0 5 (20.8) N/A N/A N/A
1 14 (58.3)
2 5 (20.8)
Duration of menstruation
(d)
6.6 (3.0) 6.0 (1.4) 5.7 (1.9) 0.26b
7.0 (3e15) 6.3 (3e9) 5.8 (3e8)
(n ¼ 18 missing)
Amount of menses (mL) 223.0 (168.5) 152.2 (68.4) 135.0 (48.5) 0.009b
193.5 (24e900) 147.5 (24e320) 125.0 (90e200)
(n ¼ 18 missing)
Length of menstrual cycle
(d)
30.6 (10.0) 30.0 (5.5) 28.2 (3.2) 0.79b
30 (15e70) 30 (20e50) 29 (25e30)
(n ¼ 18 missing)
10-cm VAS score 5.3 (2.8) 3.4 (2.8) 3.5 (2.6) 0.0006b
5.5 (0e9) 3 (0e9) 3 (0e9) 0.0006c
Uterine size (cm3) 150.9 (103.6) 186.9 (120.6) (all missing) 0.039d
123.7 (37.3e507.8) 146.9 (69.3e453.1)
(n ¼ 15 missing)
CGI
Severity scale
N/A N/A 4.1 (0.9) N/A
4 (3e6)e
CGI
Improvement scale
N/A N/A 2.6 (1.0) N/A
2.5 (1e4)
CGI
Efﬁcacy index, n (%)
N/A N/A Marked improvement/no side effect: 3 (12.5) N/A
Moderate improvement/no side effect: 6 (25.0)
Moderate improvement/no signiﬁcant side effect: 3 (12.5)
Minimal improvement/no side effect: 5 (20.8)
Minimal improvement/no signiﬁcant side effect: 3 (12.5)
Unchanged or worse/no side effect: 5 (20.8)
Data are presented as mean (SD) or median (range), unless otherwise indicated.
CGI ¼ Clinical Global Impression; N/A ¼ not applicable; SD ¼ standard deviation; VAS ¼ visual analog scale.
a All tests were paired rank-sum test unless indicated otherwise.
b The p value is for 3 months after treatment versus baseline.
c The p value is for 6 months after treatment versus baseline.
d Paired test only for the nine patients who had data at both time points.
e Moderate dysmenorrhea.
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which are the commonly used instrument to gauge a global
severity of patients' symptoms, improvement after treatment, and
the response to treatment.28 Replacing mental illness withFig. 1. Andrographolide dripping pills and the packaging box. An Apple iPod Shufﬂe (in
purple) is also shown for scaling purpose.complaints of dysmenorrhea and menorrhagia and letting the pa-
tient instead of the physician do the rating, the CGI has three
component scales: Severity Scale (CGI-S), Improvement Scale (CGI-
I), and Efﬁcacy Index. CGI-S is a 7-point scale that lets the patient
rate the severity of her dysmenorrhea/menorrhagia at the time of
assessment. A patient would rate her severity of dysmenorrhea/
menorrhagia at the time of rating as follows: 1, normal, not at all; 2,
borderline; 3, mild; 4, moderate; 5, marked; 6, severe; or 7,
extreme.
The CGI-I is a 7-point scale that asks the patient to assess how
much her dysmenorrhea/menorrhagia has improved or worsened
relative to a baseline state at the beginning of the intervention. The
rating scale was as follows: 1, very much improved; 2, much
improved; 3, minimally improved; 4, no change; 5, minimally
worse; 6, much worse; or 7, very much worse.
The Efﬁcacy Index is a 4 point 4 point rating scale that assesses
the therapeutic effect of the treatment as 1, unchanged to worse; 2,
minimal; 3, moderate; and 4, marked by side effects rated as none,
do not signiﬁcantly interfere with patient's functioning, signiﬁ-
cantly interferes with patient's functioning, and outweighs thera-
peutic effect.
Nine patients (37.5%) came to the hospital for clinical ultrasound
examination after taking Andro for 3 months. Six patients (25%)
completed the 6-month study and provided information about the
length of menstrual cycle and the amount of menses. However, all
X. Liu et al. / Gynecology and Minimally Invasive Therapy 3 (2014) 119e126122patients provided their VAS scores on dysmenorrhea and the CGI
scores over the phone.
Immunohistochemistry of the phosphorylated p65 (pp65) subunit
With an exception for ﬁve patients, a small endometrial tissue
sample was obtained by hysteroscopy for each patient after
informed consent. The sample was then ﬁxed with 10% formalin
and parafﬁn embedded. Serial 4-mm sections were obtained from
each block to conﬁrm pathologic diagnosis, and to stain for the NF-
kB p-p65 subunit, an activated form. Routine deparafﬁnization and
rehydration procedures were performed. The mouse monoclonal
antibody against phosphorylated NF-kB p-p65 (Ser 276; No. 3037,
Cell Signaling, Santa Cruz, CA, USA), diluted to 1:50, was used as a
primary antibody. For antigen retrieval, the slides were heated at
98C in an ethylenediaminetetraacetic acid buffer (pH 9.0) for 30
minutes and cooled naturally at room temperature. Sections were
then incubated overnight with the primary antibody at 4C. After
rinsing the slides, the biotinylated secondary antibody, Supervi-
sion TM Universal (antimouse/rabbit) detection reagent (horse-
radish peroxidase; GK500705, Shanghai Gene Tech Company,
Shanghai, China), was incubated at room temperature for 30 mi-
nutes. The bound antibody complexes were stained for 3e5 mi-
nutes or until appropriate for microscopic examination with
diaminobenzidine and then counterstained with hematoxylin and
mounted. Immunoreactivity staining was characterized quantita-
tively by digital image analysis using the Image Pro-Plus 6.0
(Media Cybernetics, Inc., Rockville, MD, USA) without prior
knowledge of any of the clinicopathological information.
Statistical analysis
The statistical signiﬁcance of changes in continuous variables
between before and after the treatment was made using the paired
Wilcoxon rank sum test. If the number of missing values was
considerably unequal, the unpaired Wilcoxon test was used. Pear-
son correlation coefﬁcient was used while evaluating correlations
between two variables when both variables are continuous. When
at least one variable was ordinal, Spearman rank correlation0 1 2 3 4 5 6
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Fig. 2. (A) Kinetics of the visual analog scale (VAS) scores evaluated before and 3 months a
before and 3 months and 6 months after taking the andrographolide dripping pills. Tx ¼ tcoefﬁcient was used instead. To see whether the p-p65 staining
levels decrease with less improvement in treatment outcome,
JonckheereeTerpstra trend test was used.
A p value < 0.05 was considered statistically signiﬁcant. All
computations were made with R 3.1.0 (www.r-project.org).29
Results
The characteristics of the 24 patients who were recruited to and
completed the study, along with the changes in the primary and
secondary outcome measures are presented in Table 1. In these
patients, the baseline (pretreatment) VAS score did not appear to
correlate with the uterine size (r ¼ 0.20, p ¼ 0.35).
Treatment effect on primary outcome measures
Three months after taking Andro, 15 of 24 (62.5%) patients
reported some relief of dysmenorrhea (change < 0), but eight
(33.3%) of them reported no change in the VAS score, and one
(4.2%) even reported the worsening, by 1 point, of dysmenorrhea
(Fig. 2A). Compared with the baseline, the average VAS score on
dysmenorrhea at the end of the 3-month Andro treatment was
reduced from 5.3 to 3.4, a 35.8% reduction (p ¼ 0.0006; Fig. 2B).
Six months after taking Andro or 3 months after the discontin-
uation of the treatment, 16 patients (66.7%) reported some relief
of pain, and the average VAS score was decreased from 5.3 to 3.5,
a 34.0% reduction as compared with the baseline (p ¼ 0.0006;
Fig. 2B). However, there was no statistical difference in the VAS
score between the two post-treatment evaluations (p ¼ 0.20). In
fact, compared with the VAS score evaluated at 3 months after
treatment, the majority of patients (n ¼ 21, or 87.5%) reported no
further reduction in the VAS score evaluated at 6 months
(Fig. 2B). Compared with the baseline, 16 (66.7%) patients re-
ported reduced VAS scores while the remaining eight patients
(33.3%) reported no change in or increased VAS score. Among
those who had reduced VAS scores, 10 (41.7%) reported a
reduction by two or more points.
For the nine patients (37.5%) who actually came to the hospital
for post-treatment evaluation, the ultrasonographic examinationPre-Tx            3 mo post-Tx     6 mo post-Tx
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Fig. 3. (A) Kinetics of the uterus size evaluated before and 3 months after treatment with andrographolide and (B) box plot of the uterus size before and 3 months after taking the
andrographolide dripping pills. Tx ¼ treatment.
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months after taking Andro (Fig. 3A; p ¼ 0.039).
The reduction in VAS score did not appear to correlate with the
change in uterine size before and after the treatment (r ¼ 0.09,
p ¼ 0.81 for 3 months after taking Andro vs. the baseline).Menstrual characteristics and their changes
Therewas no change in the length of menstrual cycles 3 months
after taking Andro [mean (standard deviation) ¼ 30.6 (9.6) days vs.
29.9 (5.5) days, p ¼ 0.79; Table 1 and Fig. 3]. Because only six pa-
tients reported this information, we did not perform any analysis
on data at 6 months after the treatment.
Remarkably, the amount of menses 3 months after treatment
was signiﬁcantly reduced as a result of the Andro treatmentPre-Tx    3 mo post-Tx
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Fig. 4. Box plots of the amount of menses before and 3 months after taking Andro.
Tx ¼ treatment.(p ¼ 0.009, Fig. 4), but the data at 6 months were too sparse to be
meaningful (n ¼ 6, or 25%). Although the duration of menstruation
also appeared to be reduced, the change did not reach statistical
signiﬁcance (p ¼ 0.26 for 3 months and 6 months after taking
Andro).
Clinical Global Impression
The severity of dysmenorrhea as rated by the 24 patients ranged
from 1 (no dysmenorrhea at all) to 6 (very severe, seriously inter-
fering with their daily lives and work, without any relief from
taking analgesia), with a median CGI-S score of 4, that is, moder-
ately ill (dysmenorrhea/menorrhagia; Table 1). Six months after the
treatment, three (12.5%) patients felt “marked improvement”, nine
(37.5%) reported “moderate improvement”, seven (29.2%) reported
“minimal improvement”, and ﬁve (20.8%) reported “unchanged or
worse”, with a median score of 2.5, between 2 (minimal improve-
ment) and 3 (unchanged or worse; Table 1). In all patients, no
signiﬁcant side effects were reported (Table 1).
The CGI-S scale correlated positively with the baseline VAS score
on dysmenorrhea (r ¼ 0.89, p¼ 5.4 109, Spearman's correlation)
but only marginally with the baseline amount of menses (r ¼ 0.34,
p ¼ 0.10). The CGI-I scale correlated positively with the VAS score
on dysmenorrhea evaluated at the 6th month (r ¼ 0.50, p ¼ 0.014)
but not with the amount of menses evaluated at the end of the 3rd
month (r ¼ 0.14, p ¼ 0.52). However, the CGI-I scale correlated
positively with both the change in the VAS score (r ¼ 0.77,
p ¼ 1.3  105) and the change in the amount of menses (r ¼ 0.44,
p ¼ 0.033).
Immunostaining of the phosphorylated NF-kB p65 subunit in the
endometrium and its relationship with the treatment response
We performed an immunostaining on the activated NF-kB p65
subunit in the endometrium. We found no difference in p-p65
staining level between the proliferative and secretory phases
(p ¼ 0.90). We found that the p-p65 staining levels (square root
transformed to improve normality) did not correlate with either
the baseline VAS score (r ¼ 0.25, p ¼ 0.29), baseline uterus size
(r ¼ 0.34, p ¼ 0.16), or the amount of menses (r ¼ 0.013,
X. Liu et al. / Gynecology and Minimally Invasive Therapy 3 (2014) 119e126124p ¼ 0.96). However, the staining levels were negatively associated
with the VAS scores evaluated at the 3rd month and 6th month
(r ¼ 0.47, p ¼ 0.042, and r ¼ 0.50, p ¼ 0.028, respectively). We
then wondered whether the change in dysmenorrhea VAS score
at the end of the treatment as compared with its baseline level
was associated with the immunostaining levels. We carried out a
multiple linear regression analysis on the change in VAS score
using the p-p65 immunostaining levels, the baseline VAS score,
uterus size, menstrual phase, and age as covariates. We found that
the baseline VAS score and the p-p65 staining levels were the two
variables negatively associated with the change in the VAS score
(p ¼ 0.015 and p ¼ 0.032, respectively; R2 ¼ 0.39). The scatter
plots of the change in VAS score versus the baseline VAS score
and the p-p65 staining levels are presented in Fig. 5A and B. With
regard to the change in the amount of menses at the end of the
3rd month as compared with its baseline level, no relation with
the p-p65 immunostaining levels was found (r ¼ 0.10, p ¼ 0.70).
We then evaluated the p-p65 staining levels in patients with
different rating of their impression of treatment response, and
found that, after lumping the “Very much improved” rating with
the “Much improved” rating (as there was only 1 patient who also
had p-p65 data in the 1st rating), the rating was closely correlated
with the p-p65 staining levels (p ¼ 0.011 by JonckheereeTerpstra
test; Fig. 5C). Removing the patient who rated her impression as
“Very much improved” gave a similarly signiﬁcant result
(p ¼ 0.025).
Difference between patients who were lost to follow-up and those
who were not
Given the 75% of patients who did not come for further evalu-
ation, we wondered whether there was any difference between
patients who were followed up and those who were lost to follow-
up. It seemed that, compared with those who were lost to follow-
up, those who were followed up appeared to be slightly “sicker”
and their treatment outcome seemed to be slightly better, although
the difference did not reach statistical signiﬁcance (Table 2). It is
unclear whether the lack of statistical signiﬁcance is genuine or due0 2 4 6 8
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Fig. 5. (A) Scatter plot of the change in the visual analog scale (VAS) score and the baseline V
the endometrium; and (C) box plots of the p-p65 staining levels among patients who rated th
“No change” (red). The Pearson correlation coefﬁcient, along with its p value, is shown in t
value, is shown. The green dots in Panels A and B are patients who rated their treatment outc
Panel C. (For interpretation of the references to color in this ﬁgure legend, the reader is reto the lack of statistical power. However, there was a signiﬁcant
difference in p-p65 staining levels, with those who were followed
up having higher staining levels (Table 2).
Adverse events
Andro appeared to be well tolerated by the patients. In all 24
patients who went through the 3-month period of treatment, no
adverse event, major or minor, was reported.
Discussion
To the best of our knowledge, this is the ﬁrst clinical use of an
NF-kB inhibitor in treating adenomyosis, despite extensive studies
demonstrating the role of NF-kB in the development of adeno-
myosis/endometriosis. In addition, the efﬁcacy of Andro appears to
be dependent on the extent of NF-kB activation in eutopic endo-
metrium, which might be a proxy for the activation level in ade-
nomyotic foci. Whereas Andro appears to be well tolerated, the
results seem to be mixed. Judging by the dysmenorrhea VAS scores
and the CGI scores, Andro seemed to work for about half of the
patients with symptomatic adenomyosis, especially for some with
more severe dysmenorrhea. However, for the other half of the pa-
tients who had seemingly lower canonical NF-kB activation level in
eutopic endometrium, it did not seem to have much therapeutic
effect. The somewhat high rate of lost to follow-up or of failure to
show up for follow-up examination 6 months after treatment ap-
pears to support this view.
Although the quality of life in women with symptomatic ade-
nomyosis may be reduced, adenomyosis is nonetheless a benign
disease, and by no means life-threatening. As such, the desirable
therapeutics for adenomyosis demands a stringent safety proﬁle.
Because the management of endometriosis, and likely adeno-
myosis as well, is going to be long term,30 an ideal drug should
also be inexpensive and affordable. Andro ﬁts these two
requirements.
Because even those who were lost to follow-up still provided
their VAS and CGI scores over the phone, naturally one would0.15 0.20 0.25
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Table 2
Characteristics of patients who were lost to follow-up and those who were not.
Variable Patients who were lost to follow-up
(n ¼ 18)
Patients who completed the study
(n ¼ 6)
p
Age (y) 39.8 (5.4) 41.3 (4.0) 0.31
39.5 (30e50) 41.5 (34e45)
Amount of menses (mL) 213.8 (188.7) 250.7 (91.6) 0.22
188.5 (24e900) 216.0 (167e400)
10-cm VAS score 5.3 (2.7) 5.6 (3.2) 0.84
5.5 (0e9) 5.8 (2.5e8.5)
Uterine size (cm3) 150.7 (115.0) 151.3 (66.0) 0.41
113.0 (37.3e507.8) 134.3 (93.2e271.1)
Change in VAS score at
the end of the 6th mo
1.4 (1.9) 3.0 (2.2) 0.11
0.5 (5.5e1) 2.8 (5.5e0)
Change in the amount
of menses at the end
of the 3rd mo (mL)
55.9 (181.1) 115.3 (127.6) 0.15
7.5 (770e45) 83.5 (300e0)
CGI
Severity scale
4.2 (0.9) 4.0 (0.9) 0.89
4 (3e6) 4 (3e5)
CGI
Improvement scale
2.7 (0.9) 2.2 (1.2) 0.43
3 (1e4) 2.2 (1e4)
CGI
Efﬁcacy index, n (%)
Marked improvement/no side effect: 1 (5.6) Marked improvement/no side effect: 2 (33.3) 0.68
Moderate improvement/no side effect: 5 (27.8) Moderate improvement/no side effect: 1 (16.7)
Moderate improvement/no signiﬁcant
side effect: 2 (11.1)
Moderate improvement/no signiﬁcant
side effect: 1 (16.7)
Minimal improvement/no side effect: 4 (22.2) Minimal improvement/no side effect: 1 (16.7)
Minimal improvement/no signiﬁcant
side effect: 2 (11.1)
Minimal improvement/no signiﬁcant
side effect: 0 (0.0)
Unchanged or worse/no side effect: 4 (22.2) Unchanged or worse/no side effect: 1 (16.7)
Endometrial p-p65
staining levels
0.022 (0.018)
(n ¼ 2 missing)
0.035 (0.026)
(n ¼ 2 missing)
3.1  105
Data are presented as mean (SD) and/or median (range), unless otherwise indicated.
CGI ¼ Clinical Global Impression; SD ¼ standard deviation; VAS ¼ visual analog scale.
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evaluation better than they actually were simply because they
wanted to please the interviewing physician.
In China's current health care system, all patients have the
complete freedom to choose a hospital or even doctors to their
liking, whether they have health insurance coverage or not. Many
afﬂuent patients in neighboring provinces outside Shanghai often
travel to Shanghai in the hope to get the bestmedical care. For these
patients, having a worse outcome or no change in their symptoms
could likely prompt them to go to another hospital or other phy-
sicians, but they are also likely to come back again because of their
initial trust in the hospital. Therefore, for patients who work and
live outside Shanghai, loss of follow-up does not necessarily mean a
worse outcome.
For patients residing in Shanghai, failure to show up at the
second follow-up also could mean no change or worsened condi-
tion, and they voted their conﬁdence by their feet. If they were
genuinely unhappy about their care, however, it is likely that they
would simply say so or refuse to provide more information
regarding their condition. Because Shanghai has many tertiary
hospitals and there are in fact many doctors even in our hospital,
they could have done so with impunity. In other words, the high
rate of lost to follow-up may not, again, necessarily be a sign of
treatment failure.
In view of this analysis, the VAS and CGI scores provided over
the phone can be viewed as fairly reliable. With that data, it seems
that Andro is efﬁcacious for about half of the patients. For the other
half, it simply did not seem to work well.
Then, why a compound from a drug class that holds so much
promise for treating adenomyosis/endometriosis is not even 70%
effective? Should we sack Andro based on this pilot clinical study?
As is well-known in cancer therapy or even endometriosis
treatment, no drug is 100% effective. Thus, Andro should not be an
exception. We would argue that for a condition that is notoriouslydifﬁcult to manage,31 approximately 50% efﬁcacy is rather
encouraging, particularly so given the fact that Andro has an
excellent side effect and safety proﬁle and is very affordable. More
clinical studies or clinical trials are perhaps warranted to further
evaluate its efﬁcacy.
There are in fact several reasons to explainwhy Andro treatment
did not yield its expected efﬁcacy for some patients. First, Andro
may simply elicit no response from ectopic endometrial tissues
because of the extensive presence of ﬁbrosis. Our laboratory
recently found extensive ﬁbrosis in ectopic endometrial tissues
harvested from patients who have undergone hysterectomy
because of symptomatic adenomyosis (Shen et al, unpublished
data). It is well-known that as of now there is no effective treatment
for ﬁbrosis.32
Second, Andro renders its action presumably by inhibiting the
NF-kB p50 subunit.33 As a family of structurally related dimeric
transcription factors, NF-kB has ﬁve members, namely, p50 (NF-
kB1), p52 (NF-kB2), p65 (Rel A), c-Rel, and RelB, which form various
homo- and heterodimers when activated, with the p50ep65 di-
mers being the canonical activated forms.33 Although many studies
demonstrated constitutive activation of NF-kB in endometriosis/
adenomyosis,6e8 most, if not all, of them only examined the ca-
nonical activation form, that is, the p50ep65 dimers or simply p65
activation. However, if the adenomyotic lesion has a noncanonical
activation form, then conceivably Andro treatment may not be
effective. The ﬁnding that bigger reduction in the VAS scores was
negatively associated with the p-p65 staining in the endometrium
seems to support this notion, because the higher p-p65 staining
and a better outcome appear to suggest that Andro was right on
target when the p65ep50 heterodimers were canonically activated
in the endometrium, and perhaps also in ectopic endometrium. If
this proves to be true, then perhaps individualized treatment based
on the speciﬁc NF-kB homo- and heterodimers activation may be a
way to go.
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NF-kB are involved in the development of adenomyosis, and
therefore Andro treatment may not have any effect on these
pathways.
Whatever the reasonmay be, future research is needed to clarify
(1) whether the NF-kB activation status in eutopic endometrium
can be used as a proxy for the status in ectopic endometrium in
adenomyosis; (2) whether the extent of ﬁbrosis in lesions affect
treatment efﬁcacy; and (3) which NF-kB subunits are involved in
the development of adenomyosis aside from p50ep65.
Despite being the ﬁrst in the clinical use of an NF-kB inhibitor in
treating adenomyosis, and in the use of canonical NF-kB activation
level in eutopic endometrium as a proxy for adenomyotic foci, this
study has limitations. First, caution should be exercised when
interpreting our ﬁndings because of a high rate of lost to follow-up.
Second, because of lost to follow-up, we did not have any data for
the long-term efﬁcacy of Andro. However, even if the efﬁcacy lasts
for only 3months after termination of the treatment, one could still
argue that it is worthwhile, particularly so given the excellent
safety proﬁle and the cost proﬁle of Andro.
In conclusion, we found that Andro is effective in some patients
with symptomatic adenomyosis, who have a higher endometrial
expression of the activated form of the NF-kB p65 subunit. Future
independent validation studies or randomized clinical trials may be
needed to more precisely evaluate the efﬁcacy of Andro in treating
adenomyosis.
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